The biggest challenge from the “modernization” of the US Food and Drug Administration’s Office of New Drugs over the long haul will be the agency’s continued challenges in filling open positions.
The impact is not likely to be felt in the initial phases of promoting new directors and deputies to fill the many new division- and office-level positions created in the reorganization
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?